Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) may require a more comprehensive diagnostic approach that considers interactions between the nervous system, immune responses, metabolism, and gut microbiota, according to a review published in iMetaMed.
The authors argue that CP/CPPS should no longer be viewed solely as a disorder of the prostate. Instead, emerging evidence suggests that several interconnected biological processes contribute to its diverse symptoms and variable treatment responses.
CP/CPPS can cause persistent pelvic pain, urinary difficulties, and sexual dysfunction, substantially affecting quality of life. However, diagnosis remains challenging because symptoms vary widely and reliable laboratory biomarkers are lacking.
The review examines evidence linking local prostate inflammation with changes in pain-processing pathways, immune activity, metabolism, and intestinal microorganisms.
One proposed mechanism involves persistent inflammation sensitizing pelvic nerves and altering how the central nervous system processes pain. This could explain why symptoms sometimes continue even when local inflammation has subsided.
The review highlights several potential diagnostic developments. One is the identification of candidate inflammatory biomarkers in expressed prostatic secretions, including the NLRP3 inflammasome, alongside changes in cytokines and metabolic profiles. These findings could eventually help distinguish biological subtypes of CP/CPPS.
The authors also examine multiparametric magnetic resonance imaging, microbiome analysis, and symptom-based assessment tools as possible components of a more personalized diagnostic pathway.
Combining these approaches could help clinicians identify the mechanisms driving an individual patient's symptoms and select appropriate treatments, rather than relying on empirical therapy.
Potential therapeutic strategies include neuromodulation, interventions targeting inflammatory and metabolic pathways, microbiota-directed treatments, and integrated psychological support.
However, the authors emphasize that much of the supporting evidence comes from small observational studies, genetic analyses, or preclinical experiments. Existing candidate biomarkers and imaging techniques cannot yet reliably distinguish CP/CPPS subtypes.
Prospective studies and clinical trials will be essential to validate biomarkers, establish clinically meaningful patient subgroups, and determine whether mechanism-guided treatment improves outcomes.
Newsletters
Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.
